ABOUT NANOLOGICA
Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers.
Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity.
The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.
NLAB Saga®
A NEW GENERATION SILICA FOR PREPARATIVE CHROMATOGRAPHY
NLAB Saga® is a perfectly spherical, fully porous silica with superior mechanical stability and exceptional
chemical stability at high and low pH, making it an optimum choice for large scale purification of peptides.
News
Number of Shares and Votes in Nanologica AB (publ)
30 June, 2025
The number of registered shares and votes in Nanologica AB has changed during the month of June following the registration of exercised warrants of series TO5. In 2024, Nanologica issued a total of 11,044,654 warrants of series TO5 within the framework of a rights issue of units. During the period May 7, 2025 to May
Statement from the Board of Directors of Nanologica AB (publ) Regarding the Mandatory Bid from Flerie Invest AB
13 June, 2025
The Board of Directors of Nanologica AB (publ) (“Nanologica” or the “Company”) unanimously recommends the shareholders of Nanologica not to accept the mandatory cash offer made by Flerie Invest AB (“Flerie”) on May 23, 2025. This statement is made by the Board of Directors of Nanologica in accordance with section II.19 of the Takeover Rules
Listen to our team talk about Nlab Saga®
Interview with Katarina Alenäs,
SVP Chromatography
Interview with Olga Krivosheeva, Ph.D.
Application Project Manager
Interview with Chunfang Zhou, Ph.D.
Sales Manager China
Nanologica is a public company listed for trade on Nasdaq Stockholm Main Market. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.
Presentation of Nanologica
For more videos presentations of the company and of interim reports, please refer to Investor Relations.
Company presentation made by CEO Andreas Bhagwani in June, 2023.
Investor Pitch Deck November 2024.
Please contact us at ir@nanologica.com for more information.